Ribo and Boehringer Ingelheim collaborate to develop treatments for NASH and MASH

Jan. 3, 2024

Suzhou Ribo Life Science Co. Ltd. and Ribocure AB have entered into a collaboration with Boehringer Ingelheim Pharma GmbH & Co. KG to develop novel treatments for nonalcoholic or metabolic dysfunction-associated steatohepatitis (NASH/MASH).

BioWorld Science RNA Collaboration Gastrointestinal

Today's news in brief

BioWorld

BioWorld briefs for June 5, 2026.

News in brief

BioWorld Asia

BioWorld Asia briefs for June 2, 2026

Janssen Pharmaceutica reports new TMEM175 activators

BioWorld Science

Janssen Pharmaceutica NV has identified new endosomal/lysosomal proton channel TMEM175 activators that are potentially useful for the treatment of Parkinson’s...

Cancer specter looming, Abtect effect in UC wallops Abivax

BioWorld

Although analysts liked the data – calling them “truly amazing” and “transformational” – Wall Street apparently had qualms about three cancer cases that turned up...

FB-7033 demonstrates efficacy in MASH management

BioWorld Science

17-β-Hydroxysteroid dehydrogenase 13 (HSD17B13) and lipid transferase CIDEB are known to contribute to metabolic dysfunction-associated steatohepatitis (MASH)...